Impact of the COVID-19 Pandemic on the Delivery of Dermatological Care.
Kimball, Alexa B, and Martina L Porter. 2022. “Impact of the COVID-19 Pandemic on the Delivery of Dermatological Care.”. Current Dermatology Reports 11 (4): 313-17.
Search
Search results
399 results found
Dermatologic inflammatory conditions require high loading and maintenance doses of biologic therapy.
Greif, C, M L Porter, and A B Kimball. 2022. “Dermatologic Inflammatory Conditions Require High Loading and Maintenance Doses of Biologic Therapy.”. Journal of the European Academy of Dermatology and Venereology : JEADV 36 (10): e786-e788.
Effects of swimming on facial sebum in adolescents.
Morss-Walton, Peyton C, Ranch Kimball, Monica Rosales Santillan, Jean S McGee, Anthony Cukras, Sachin Patwardhan V, Martina L Porter, and Alexa B Kimball. 2022. “Effects of Swimming on Facial Sebum in Adolescents.”. Pediatric Dermatology 39 (3): 376-78.
Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study.
Stevens, Jennifer P, Oren Mechanic, Lawrence Markson, Ashley O’Donoghue, and Alexa B Kimball. 2021. “Telehealth Use by Age and Race at a Single Academic Medical Center During the COVID-19 Pandemic: Retrospective Cohort Study.”. Journal of Medical Internet Research 23 (5): e23905.
Hidradenitis suppurativa for the dermatologic hospitalist.
Charrow, Alexandra, Kevin T Savage, Kelsey Flood, and Alexa B Kimball. 2019. “Hidradenitis Suppurativa for the Dermatologic Hospitalist.”. Cutis 104 (5): 276-80.
Biologic Treatment for Hidradenitis Suppurativa.
Flood, Kelsey S, Martina L Porter, and Alexa B Kimball. 2019. “Biologic Treatment for Hidradenitis Suppurativa.”. American Journal of Clinical Dermatology 20 (5): 625-38.
Reliability of the hidradenitis suppurativa clinical response in the assessment of patients with hidradenitis suppurativa.
Kimball, A B, A Ganguli, and A Fleischer. 2018. “Reliability of the Hidradenitis Suppurativa Clinical Response in the Assessment of Patients With Hidradenitis Suppurativa.”. Journal of the European Academy of Dermatology and Venereology : JEADV 32 (12): 2254-56.
Adalimumab alleviates skin pain in patients with moderate-to-severe hidradenitis suppurativa: Secondary efficacy results from the PIONEER I and PIONEER II randomized controlled trials.
Kimball, Alexandra B, Murali Sundaram, Alan L Shields, Stacie Hudgens, Martin Okun, Catherine Foley, and Arijit Ganguli. 2018. “Adalimumab Alleviates Skin Pain in Patients With Moderate-to-Severe Hidradenitis Suppurativa: Secondary Efficacy Results from the PIONEER I and PIONEER II Randomized Controlled Trials.”. Journal of the American Academy of Dermatology 79 (6): 1141-43.
Overview and update on biologic therapy for moderate-to-severe hidradenitis suppurativa.
Porter, Martina L, Nicole M Golbari, Stephen J Lockwood, and Alexa B Kimball. 2018. “Overview and Update on Biologic Therapy for Moderate-to-Severe Hidradenitis Suppurativa.”. Seminars in Cutaneous Medicine and Surgery 37 (3): 182-89.
Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson, C C, and A B Kimball. 2004. “Rethinking the Psoriasis Area and Severity Index: The Impact of Area Should Be Increased.”. The British Journal of Dermatology 151 (2): 381-7.